Financial Performance - For the fiscal year ended December 31, 2024, the company recorded net sales of 6,783.6million,adeclineof2.61,084.8 million, reflecting a significant increase from 696.4millionin2023[176].−AdjustedEBITDAfor2024was1,198.8 million, a decrease of 110.3millionfrom2023,resultinginanAdjustedEBITDAmarginof17.7128.2 million or 2.7%, while the Bioscience Production segment experienced a decline of 55.4millionor2.5711.5 million, an increase of 390.4millioncomparedto2023,attributedtohigheroperatingincomeandlowerinterestexpenses[190].−AdjustedOperatingIncomedecreasedby122.0 million or 10.1% in 2024, with a decline driven by lower sales volume and higher annual incentive compensation expenses[194]. - Free cash flow for 2024 was 768.3million,anincreaseof44.7 million from 723.6millionin2023[216].CustomerRelationships−Avantor′snetsalesin2024wereapproximately86300 million in annual gross run-rate savings by the end of 2026[69]. - Strategic acquisitions are part of the growth strategy, but they carry risks such as potential adverse effects on business relationships and the assumption of substantial liabilities[72]. - The company plans to continue expanding its commercial sales operations both domestically and internationally while managing its restructuring activities[70]. Risk Management - The company faces risks related to compliance with complex data privacy regulations, which could result in significant fines and operational changes if not adhered to[87]. - Cybersecurity measures are in place, but the company remains vulnerable to cyberattacks that could disrupt operations and compromise data[84]. - The company has implemented a comprehensive cybersecurity risk management program aligned with NIST standards, including annual risk assessments[132]. Financial Position - The company has significant indebtedness, which could limit operational flexibility and increase vulnerability to economic downturns[122]. - The company currently has no plans to pay cash dividends on its common stock, which may limit returns on investment unless shares are sold at a higher price[124]. - Total liquidity as of December 31, 2024, was 1,341.1million,including261.9 million in cash and cash equivalents[210].